A new two-year research collaboration in the UK will attempt to develop digital tools that could be used alongside approved therapies for people with dementia.
The Bill and Melinda Gates Foundation has spun out a not-for-profit biotech company that will focus on finding treatments for diseases that predominantly affect the poor.
AbbVie has moved to shore up its pipeline following the loss of patent protection for its top-selling drug with a $10.1 billion deal to buy ImmunoGen and its marketed ovar
On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio